{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28","upperLimit":"72","value":"50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"time to disease progression or death due to any cause","dispersionType":"95% Confidence Interval","groups":[{"description":"Eligible patients are treated with busulfan IV over 2 hours on days -7 to -4, cyclophosphamide IV over 2 hours on days -3 and -2, antithymocyte globulin (ATG) IV over 10 hours on days -3 to -1 (BuCyATG) and cord blood is infused on day 0; or are treated with cyclophosphamide IV over 2 hours on days -5 and -4, antithymocyte globulin (ATG) IV over 10 hours on days -3 to -1, and undergo TBI twice a day on days -3 to -1 (CyATGTBI) and cord blood is infused on day 0","id":"OG000","title":"Arm 1"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"% of participants"}